NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21
Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…
Wayne Gretzky’s enduring observation that hard work in youth can create freedom later is more than a hockey maxim. It is a compact description of how durable companies and long-term investor build advantage: do the unglamorous work early, develop pattern recognition before…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
U.S. stocks finished broadly higher on Wednesday, August 19, as a pullback in long-dated Treasury yields improved risk appetite, a pause in proposed Canadian tariffs reduced a near-term trade overhang, and a landmark oncology update sparked an extraordinary biotech rally. The S&P…
The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has delivered the kind of Phase 3 result biotechnology investors wait patiently—and, on occasion, not so patiently—for. The company reported that avexitide reduced the composite rate of severe and clinically meaningful post-bariatric hypoglycemia events by 55% versus…
